免疫疗法治疗的晚期癌症患者中，根据中性粒细胞与淋巴细胞比率状态的血脂谱差异影响
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.
作者信息
Perrone Fabiana, Pecci Federica, Maffezzoli Michele, Giudice Giulia Claire, Cognigni Valeria, Mazzaschi Giulia, Cantini Luca, Santamaria Luca, Paoloni Francesco, Bruno Rocchi Marco Luigi, Coriano' Matilde, Acunzo Alessandro, Quaini Federico, Tiseo Marcello, Kamal Saini S, Berardi Rossana, Buti Sebastiano
机构信息
Medical Oncology Unit, University Hospital of Parma, Parma.
Department of Medicine & Surgery, Parma, University of Parma, Parma.
出版信息
Immunotherapy. 2024;16(13):859-868. doi: 10.1080/1750743X.2024.2377953. Epub 2024 Aug 6.
To investigate the different impact of each component of lipid profile in advanced cancer patients treated with immune checkpoints inhibitors (ICIs) according to neutrophil-to-lymphocyte ratio (NLR) value. We retrospectively collected total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL). 407 patients were enrolled. In NLR <4 subgroup, TGs <150 mg/dl led to longer PFS ( = 0.01) and OS ( = 0.02) compared with TGs ≥150 mg/dl; LDL <100 mg/dl led to longer PFS ( = 0.004) and OS ( = 0.007) compared with LDL ≥100 mg/dl. In NLR ≥4 subgroup, TC >200 mg/dl led to longer PFS ( = 0.008) and OS ( = 0.004) compared with TC <200 mg/dl. We showed a distinct prognostic impact of lipid profile according to NLR.
根据中性粒细胞与淋巴细胞比值（NLR）值，研究脂质谱各成分对接受免疫检查点抑制剂（ICI）治疗的晚期癌症患者的不同影响。我们回顾性收集了总胆固醇（TC）、甘油三酯（TGs）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）。共纳入407例患者。在NLR<4亚组中，与TGs≥150mg/dl相比，TGs<150mg/dl导致更长的无进展生存期（PFS，P=0.01）和总生存期（OS，P=0.02）；与LDL≥100mg/dl相比，LDL<100mg/dl导致更长的PFS（P=0.004）和OS（P=0.007）。在NLR≥4亚组中，与TC<200mg/dl相比，TC>200mg/dl导致更长的PFS（P=0.008）和OS（P=0.004）。我们发现根据NLR，脂质谱具有明显的预后影响。
Zotero 插件